These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

166 related articles for article (PubMed ID: 10775794)

  • 1. An investigation of the intradermal route as an effective means of immunization for microparticulate vaccine delivery systems.
    Puri N; Weyand EH; Abdel-Rahman SM; Sinko PJ
    Vaccine; 2000 May; 18(23):2600-12. PubMed ID: 10775794
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Adjuvancy enhancement of muramyl dipeptide by modulating its release from a physicochemically modified matrix of ovalbumin microspheres. II. In vivo investigation.
    Puri N; Sinko PJ
    J Control Release; 2000 Oct; 69(1):69-80. PubMed ID: 11018547
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Adjuvanted, antigen loaded N-trimethyl chitosan nanoparticles for nasal and intradermal vaccination: adjuvant- and site-dependent immunogenicity in mice.
    Bal SM; Slütter B; Verheul R; Bouwstra JA; Jiskoot W
    Eur J Pharm Sci; 2012 Mar; 45(4):475-81. PubMed ID: 22009113
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Oral delivery of poly(lactide-co-glycolide) microspheres containing ovalbumin as vaccine formulation: particle size study.
    Uchida T; Goto S
    Biol Pharm Bull; 1994 Sep; 17(9):1272-6. PubMed ID: 7841952
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Intradermal delivery of vaccine nanoparticles using hollow microneedle array generates enhanced and balanced immune response.
    Niu L; Chu LY; Burton SA; Hansen KJ; Panyam J
    J Control Release; 2019 Jan; 294():268-278. PubMed ID: 30572036
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Enhancing immunogenicity and reducing dose of microparticulated synthetic vaccines: single intradermal administration.
    Carcaboso AM; Hernández RM; Igartua M; Rosas JE; Patarroyo ME; Pedraz JL
    Pharm Res; 2004 Jan; 21(1):121-6. PubMed ID: 14984266
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Topical imiquimod is a potent adjuvant to a weakly-immunogenic protein prototype vaccine.
    Johnston D; Bystryn JC
    Vaccine; 2006 Mar; 24(11):1958-65. PubMed ID: 16310898
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Intradermal Delivery of Antigens Enhances Specific IgG and Diminishes IgE Production: Potential Use for Vaccination and Allergy Immunotherapy.
    Yasuda T; Ura T; Taniguchi M; Yoshida H
    PLoS One; 2016; 11(12):e0167952. PubMed ID: 27973543
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Administration routes affect the quality of immune responses: A cross-sectional evaluation of particulate antigen-delivery systems.
    Mohanan D; Slütter B; Henriksen-Lacey M; Jiskoot W; Bouwstra JA; Perrie Y; Kündig TM; Gander B; Johansen P
    J Control Release; 2010 Nov; 147(3):342-9. PubMed ID: 20727926
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Efficient antigen delivery to the draining lymph nodes is a key component in the immunogenic pathway of the intradermal vaccine.
    Tozuka M; Oka T; Jounai N; Egawa G; Ishii KJ; Kabashima K; Takeshita F
    J Dermatol Sci; 2016 Apr; 82(1):38-45. PubMed ID: 26674124
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Microsphere translocation and immunopotentiation in systemic tissues following intranasal administration.
    Eyles JE; Bramwell VW; Williamson ED; Alpar HO
    Vaccine; 2001 Sep; 19(32):4732-42. PubMed ID: 11535324
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Comparative study of the effects of peptidoglycan monomer and structurally related adamantyltripeptides on humoral immune response to ovalbumin in the mouse.
    Tomasić J; Hanzl-Dujmović I; Spoljar B; Vranesić B; Santak M; Jovicić A
    Vaccine; 2000 Jan; 18(13):1236-43. PubMed ID: 10649625
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Squalane-based emulsion vaccine delivery system: composition with murabutide activate Th1 response.
    Kantipakala R; Bonam SR; Vemireddy S; Miryala S; Halmuthur M SK
    Pharm Dev Technol; 2019 Mar; 24(3):269-275. PubMed ID: 29688119
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The administration route is decisive for the ability of the vaccine adjuvant CAF09 to induce antigen-specific CD8(+) T-cell responses: The immunological consequences of the biodistribution profile.
    Schmidt ST; Khadke S; Korsholm KS; Perrie Y; Rades T; Andersen P; Foged C; Christensen D
    J Control Release; 2016 Oct; 239():107-17. PubMed ID: 27574990
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Development of PLGA nanoparticle loaded dissolving microneedles and comparison with hollow microneedles in intradermal vaccine delivery.
    Mönkäre J; Pontier M; van Kampen EEM; Du G; Leone M; Romeijn S; Nejadnik MR; O'Mahony C; Slütter B; Jiskoot W; Bouwstra JA
    Eur J Pharm Biopharm; 2018 Aug; 129():111-121. PubMed ID: 29803720
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The muramyl dipeptide analog GMTP-N-DPG preferentially induces cellular immunity to soluble antigens.
    Fast DJ; Vosika GJ
    Vaccine; 1997 Nov; 15(16):1748-52. PubMed ID: 9364678
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Characterization of protein-adjuvant coencapsulation in microparticles for vaccine delivery.
    Mathew S; Lendlein A; Wischke C
    Eur J Pharm Biopharm; 2014 Jul; 87(2):403-7. PubMed ID: 24747810
    [TBL] [Abstract][Full Text] [Related]  

  • 18. pH Sensitive phosphorylated chitosan hydrogel as vaccine delivery system for intramuscular immunization.
    Wei J; Xue W; Yu X; Qiu X; Liu Z
    J Biomater Appl; 2017 May; 31(10):1358-1369. PubMed ID: 28387574
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Intradermal immunization with novel plasmid DNA-coated nanoparticles via a needle-free injection device.
    Cui Z; Baizer L; Mumper RJ
    J Biotechnol; 2003 Apr; 102(2):105-15. PubMed ID: 12697387
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Hyaluronan-based dissolving microneedles with high antigen content for intradermal vaccination: Formulation, physicochemical characterization and immunogenicity assessment.
    Leone M; Priester MI; Romeijn S; Nejadnik MR; Mönkäre J; O'Mahony C; Jiskoot W; Kersten G; Bouwstra JA
    Eur J Pharm Biopharm; 2019 Jan; 134():49-59. PubMed ID: 30453025
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.